Destabilization of the Dystrophin-Glycoprotein Complex without Functional Deficits in α-Dystrobrevin Null Muscle by Bunnell, Tina M. et al.
Destabilization of the Dystrophin-Glycoprotein Complex
without Functional Deficits in a-Dystrobrevin Null
Muscle
Tina M. Bunnell
1., Michele A. Jaeger
2., Daniel P. Fitzsimons
3, Kurt W. Prins
1, James M. Ervasti
1*
1Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, United States of America, 2Program in Cellular and
Molecular Biology, University of Wisconsin, Madison, Wisconsin, United States of America, 3Department of Physiology, University of Wisconsin, Madison, Wisconsin,
United States of America
Abstract
a-Dystrobrevin is a component of the dystrophin-glycoprotein complex (DGC) and is thought to have both structural and
signaling roles in skeletal muscle. Mice deficient for a-dystrobrevin (adbn
2/2) exhibit extensive myofiber degeneration and
neuromuscular junction abnormalities. However, the biochemical stability of the DGC and the functional performance of
adbn
2/2 muscle have not been characterized. Here we show that the biochemical association between dystrophin and b-
dystroglycan is compromised in adbn
2/2 skeletal muscle, suggesting that a-dystrobrevin plays a structural role in stabilizing
the DGC. However, despite muscle cell death and DGC destabilization, costamere organization and physiological
performance is normal in adbn
2/2 skeletal muscle. Our results demonstrate that myofiber degeneration alone does not
cause functional deficits and suggests that more complex pathological factors contribute to the development of muscle
weakness in muscular dystrophy.
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Introduction
The dystrophin-glycoprotein complex (DGC) is comprised of
dystrophin, the dystroglycans (a and b), the sarcoglycans (a, b, c
and d), sarcospan, the syntrophins (a1, b1, b2) and a-dystrobrevin
[1]. In skeletal muscle, this large complex of membrane-associated
proteins links the sub-sarcolemmal actin cytoskeleton to the
extracellular matrix and is thought to provide protection from
stresses imposed during muscle contraction [2]. Mutations in
several DGC components result in muscular dystrophy in both
humans and a variety of animal models. Dystrophin is one of the
best characterized DGC proteins and its absence in humans and
the mdx mouse leads to a destabilization of the DGC, sarcolemmal
fragility, myofiber degeneration and muscle weakness [3]. The
absence of functional sarcoglycans (a-b-c-and d-) or dystroglycan
also result in muscular dystrophies with similar pathological
features [4–6].
a-Dystrobrevin is a dystrophin-related protein that binds
directly to dystrophin, syntrophin, and the sarcoglycan complex
[7–10]. In addition, a-dystrobrevin binds to the intermediate
filament proteins syncoilin and synemin, thereby linking the DGC
to the intermediate filament network [11,12]. The importance of
a-dystrobrevin in maintaining healthy muscle is demonstrated by
the a-dystrobrevin null (adbn
2/2) mouse, which exhibits extensive
myofiber degeneration [13]. However, several important questions
remain regarding the function of a-dystrobrevin and the
relationship of the adbn
2/2 muscle phenotype to other dystrophic
animal models. In particular, whether the absence of a-
dystrobrevin leads to DGC instability or causes deficits in muscle
function remain to be assessed.
To further investigate the consequences of a-dystrobrevin
deficiency, we examined the biochemical stability of the DGC
and also measured the in vivo and ex vivo physiological performance
of adbn
2/2 muscle. Our results suggest that the interaction
between dystrophin and b-dystroglycan is compromised by the loss
of a-dystrobrevin, implicating a role for a-dystrobrevin in
stabilizing the DGC. However, muscle function was not
compromised in adbn
2/2 mice, which demonstrates that substan-
tial muscle cell necrosis can occur without adverse effect on
physiological performance.
Results
a-dystrobrevin biochemically stabilizes the DGC
We first assessed general histopathology by performing
hematoxylin and eosin-phloxine staining on quadriceps, gastroc-
nemius and tibialis anterior muscles from 7 month old adbn
+/2 and
adbn
2/2 mice (Fig. 1; tibialis anterior muscle not shown).
Consistent with the findings of Grady et al. [13], adbn
2/2 skeletal
muscle exhibited pockets of centrally-nucleated fibers, indicating
that muscle degeneration and regeneration had occurred. Overall,
approximately 50% of the fibers contained central nuclei in all
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which DGC components have been ablated [14–20], we observed
no evidence of fibrosis, mononuclear cell infiltration or adipose
deposition.
Previous work implicated a-dystrobrevin as a linker protein
between dystrophin and the sarcoglycan complex [10]. To assess
whether a-dystrobrevin may play a structural role within the
DGC, we measured the biochemical stability of the dystrophin-
dystroglycan interaction in adbn
2/2 mice. Since it was initially
reported that adbn
2/2 mice exhibit a progressive myopathy [13]
we measured the biochemical stability of the DGC at both 2 and 7
months of age. Western blot analysis of SDS homogenates
confirmed the absence of a-dystrobrevin in adbn
2/2 muscle
(Fig. 2A). Total muscle lysates from adbn
+/2 and adbn
2/2 muscle
also exhibited comparable levels of dystrophin (Fig. 2A) and b-
dystroglycan (data not shown), consistent with reports from Grady
et al. [21]. However, upon enrichment of the DGC from
digitonin-solubilized muscle by wheat germ agglutinin (WGA)
chromatography [22], dystrophin immunoreactivity in adbn
2/2
muscle was significantly reduced to 26% and 30% of that in adbn
+/
2 muscle at 2 and 7 months of age, respectively (Fig. 2B and 2C).
These data indicate that the biochemical interaction of dystrophin
with the dystroglycan complex is compromised in the absence of
a-dystrobrevin.
Costameres are structurally normal in adbn
2/2 muscle
It was previously shown that the dystrophin-deficient mdx mouse
exhibits altered costamere organization [23,24] and impaired
costamere anchorage to the sarcolemma [25]. In addition to its
association with dystrophin, a-dystrobrevin interacts both directly
and indirectly with several intermediate filament proteins within
the costameric network [11,12]. Similar to the mdx mouse, mice
deficient for desmin, an intermediate filament protein that
interacts indirectly with a-dystrobrevin via its association with
syncoilin [11,26], display a loss of costamere structure in certain
muscles [27]. Given that a-dystrobrevin interacts with proteins
necessary for proper costamere formation and stabilizes the DGC
(Fig. 2), we investigated costamere organization in adbn
2/2 mice.
Both wild-type and adbn
2/2 skeletal muscle at 7 months of age
exhibited highly organized rectilinear costamere structures with
predominate dystrophin staining at the Z-line, finer transverse
elements in register with the M-line and longitudinal elements
(Fig. 3). These results indicate that a-dystrobrevin is not required
for proper costamere organization.
Figure 1. Histology of adbn
+/2 and adbn
2/2 muscle. Shown are
representative hematoxylin and eosin stained sections of quadriceps
and gastrocnemius muscle from 7 month adbn
+/2 and adbn
2/2 mice.
Focal areas of centrally-nucleated fibers are evident throughout adbn
2/
2 muscles, indicative of myofiber degeneration and regeneration.
doi:10.1371/journal.pone.0002604.g001
Figure 2. a-Dystrobrevin biochemically stabilizes the DGC. (A)
Representative immunoblots for a-dystrobrevin and dystrophin from
SDS-solubilized skeletal muscle. (B) Representative immunoblots for b-
dystroglycan and dystrophin from digitonin-solubilized skeletal muscle
enriched for the DGC using WGA-chromatography. (C) Quantification of
the relative levels of dystrophin, after normalizing to b-dystroglycan
intensity, from muscle solubilates incubated with WGA-agarose beads.
Asterisks denotes a significant (one-sample t-test, p,0.05) reduction in
the levels of dystrophin. n=3 for each genotype/time point; error bars
represent s.e.m.
doi:10.1371/journal.pone.0002604.g002
Figure 3. Normal costameres in adbn
2/2 muscle. Longitudinal
cryosections of quadriceps from 7 month old mice stained with Rabbit 2
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2/2 mice
To investigate the functional consequences of DGC instability
(Fig. 2) and muscle cell death (Fig. 1) in adbn
2/2 mice, we assessed
ex vivo and in vivo physiological performance using established
techniques. Contractile properties of isolated extensor digitorum
longus (EDL) muscles from adbn
+/2 and adbn
2/2 mice were
determined at 2 and 7 months of age (Table 1). At both ages,
isometric twitch force and specific force did not significantly differ
between control and null muscle. Furthermore, adbn
2/2 muscle
did not show an increased force drop after four eccentric
contractions (ECCs). Since work done to stretch the muscle is
the best predictor of the magnitude of contraction-induced injury
[28], we calculated the combined work from all four ECCs and did
not observe a significant difference between adbn
+/2 and adbn
2/2
muscle. In addition, we did not see an increase in Procion orange
infiltration of adbn
2/2 myofibers compared to control after
eccentric contractions (data not shown), indicating that sarcolem-
mal stability is not affected in adbn
2/2 muscle.
Total body strength was assessed by measuring whole-body
tension (WBT), defined as the forward pulling tension exerted by
an individual mouse in response to a tail pinch stimulus [29].
Maximal responses (WBT1) and the average of the top five
responses (WBT1–5) did not differ between adbn
+/2 and adbn
2/2
animals at either 2 or 7 months of age (Fig. 4A). To evaluate the
endurance capacity of adbn
2/2 mice, maximal exercise perfor-
mance tests were carried out using an uphill treadmill running
regimen. At 7 months of age adbn
2/2 mice displayed similar times
to exhaustion as adbn
+/2 mice (Fig. 4B). Together, these data
demonstrate that despite biochemical destabilization of the DGC
and substantial muscle necrosis, adbn
2/2 mice exhibit normal
skeletal muscle function.
Discussion
Since the initial observation that adbn
2/2 mice exhibit skeletal
and cardiac muscle cell necrosis [13], the adbn
2/2 mouse has been
considered an animal model for muscular dystrophy. However, as
muscular dystrophy is characterized by both muscle cell death and
muscle weakness, we examined the functional performance of
adbn
2/2 muscle. Surprisingly, adbn
2/2 muscle was indistinguish-
able from control muscle using both in vivo and ex vivo analyses.
These results were unanticipated, as adbn
2/2 mice exhibit an
elevated presence of centrally-nucleated fibers similar to other
mouse models of muscular dystrophy [13]. Although the exact
cause(s) of muscle cell death and weakness in muscular dystrophy
remains to be determined, it is reasonable to postulate that cell
death contributes to the development of muscle weakness. Our
results suggest that a more complex pathomechanism underlies the
decreased physiological performance associated with muscular
dystrophies.
Some fundamental differences in the histological observations
between adbn
2/2 mice and other DGC-associated muscular
dystrophy mouse models may help to explain the lack of a
functional deficit in adbn
2/2 mice. Unlike muscle from dystrophin-
, sarcoglycan- and dystroglycan-deficient animals [14–20], adbn
2/
2 muscle does not exhibit significant fibrosis, mononuclear cell
infiltration or increased membrane damage. Therefore, fibrosis,
inflammation and membrane fragility may be factors contributing
to the force deficits observed in dystrophic animal models. In fact,
replacement of muscle fibers with less elastic fibrotic connective
tissue has previously been suggested to contribute to decreased
force production [30]. Furthermore, treatment of dystrophic mice
and humans with corticosteroids, which is believed to help reduce
inflammation, improves muscle function [31,32], supporting the
idea that inflammation also contributes to muscle weakness.
While the cause of muscle cell death in DGC-related muscular
dystrophies is unclear, a leading hypothesis is that damage to the
sarcolemma during muscle contraction causes a loss of calcium
homeostasis, leading to activation of proteases and eventual cell
death [33]. However, similar to our findings in adbn
2/2 mice,
Warner et al. [34] report that Dp260/mdx mice exhibit muscle cell
necrosis in the absence of sarcolemmal damage. These results
indicate that sarcolemmal instability is not the sole cause of cell
death. In the absence of sarcolemmal fragility, it has been
hypothesized that cell death in adbn
2/2 mice results from aberrant
signaling. Grady et al. [13] demonstrated a loss of sarcolemmal-
localized neuronal nitric oxide synthase (nNOS) and impaired
nNOS signaling in adbn
2/2 mice [13]. Impaired nNOS signaling
leads to vasoconstriction and thereby decreased blood flow in
Table 1. Morphometric and contractile properties of EDL
muscle.






n=3 n=3 n=6 n=6
Lo (mm) 11.360.3 11.560.5 12.560.2 12.060.2
EDL mass (mg) 12.261.7 10.461.4 12.460.8 11.460.6
TPT (ms) 7.860.4 7.860.2 9.960.5 10.160.6
RT1/2 (ms) 8.361.8 11.363.1 13.160.9 12.560.7
Twitch force (mN) 22.064.0 28.667.9 45.065.1 34.164.0
Twitch force (mN/mm
2) 10.462.7 14.562.8 22.263.8 16.761.7
Tetanic force (mN) 238.2638.2 247.3646.3 395.268.3 340.0628.6
Tetanic force (mN/mm
2) 111.4627.3 127.1612.7 190.1615.8 166.168.6
Force drop (%) 24.164.3 33.068.6 20.561.8 22.064.8
Work (J/kg) 136.6630.8 167.9613.6 213.1617.0 197.267.0
Results are presented as mean6s.e.m.
TPT, time to peak tension; RT1/2, half relaxation time
doi:10.1371/journal.pone.0002604.t001
Figure 4. adbn
2/2 mice exhibit normal physiological perfor-
mance in vivo. (A) Whole-body tension analysis depicting averages of
the maximal response (WBT1) and the top five responses (WBT1–5)a t2
and 7 months of age. n$3 for each genotype/time point. (B) Time to
exhaustion during uphill treadmill running at 7 months of age. n=4 for
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focal areas of necrosis observed in adbn
2/2 mice, which is similar
to the histology of d-sarcoglycan null mice in which vascular
function is perturbed [36]. However, the loss of nNOS alone is
unlikely to account for the dystrophy in adbn
2/2 mice since
nNOS-deficient mice are not detectably dystrophic [37]. The
question therefore remains as to what causes cell death in the
absence of sarcolemmal damage. Understanding the mechanism
underlying muscle degeneration in adbn
2/2 mice may provide
insight into the molecular and cellular requirements for muscle cell
death in other animal models of muscular dystrophy.
While it has previously been proposed that a-dystrobrevin plays
a structural role in the DGC [10–12], we provide the first direct
evidence that a-dystrobrevin helps to biochemically stabilize the
interaction of dystrophin with the dystroglycan complex. Prior
immunohistochemical analyses in adbn
2/2 mice have suggested
that all other DGC components are expressed at normal levels and
localize properly to the sarcolemma [13]. Similarly, we found that
total dystrophin levels were equivalent in control and adbn
2/2
skeletal muscle extracts, but reduced by 70% in DGC-enriched
fractions from adbn
2/2 muscle. This result suggests that the
association between dystrophin and the glycoprotein complex is
compromised in the absence of a-dystrobrevin. Although the
destabilization of the DGC may contribute to the muscle cell
necrosis in adbn
2/2 mice, it appears that the degree of dystrophin
destabilization is insufficient to render the membrane susceptible
to damage, cause costamere disorganization or alter the functional
performance of the skeletal muscle. Furthermore, the upregulation
of the cytoskeletal protein syncoilin [38] may be providing
compensatory structural stabilization to the sarcolemma in the
absence of a-dystrobrevin.
In addition to the sarcolemma, a-dystrobrevin is also enriched
at the neuromuscular junction (NMJ). Previous work has shown
that adbn
2/2 mice exhibit defects in the maturation and
maintenance of the postsynaptic membrane at the NMJ as the
result of increased mobility and turnover of acetylcholine receptors
(AChRs) [21,39]. Similarly, dystroglycan deficiency also disrupts
the organization and stability of AChR clusters [40]. These studies
suggest that the DGC is important for anchoring AChRs at
synapses and maintaining postsynaptic receptor density at the
NMJ. Our data illustrating the instability of the DGC in adbn
2/2
mice provides a possible explanation for the increased AChR
mobility. While acetylcholinesterase (AChE) mobility is also
increased in adbn
2/2 mice [41], it is unclear whether this is an
indirect result of changes in AChRs or whether a-dystrobrevin and
the DGC play a direct role in AChE stability. Nonetheless,
disruption of AChE stability could result in prolonged muscle
hyperexcitability, which over time may contribute to the observed
cell death in adbn
2/2 mice. In support of this idea, mutations in
the Caenorhabditis elegans dystrobrevin-like gene cause hypercon-
tractility, which leads to muscle degeneration when on a sensitized
background [42].
Study of the adbn
2/2 mouse has provided insight into the
pathological factors that contribute to the development of
muscular dystrophy. The observation that muscle cell necrosis
and functional deficits are separable phenotypes forces us to
reconsider the traditional view that muscle cell death is a causative
factor for muscle weakness in muscle diseases. Furthermore, the
adbn
2/2 mouse suggests that membrane fragility is not the sole
contributing factor for muscle cell death in DGC-related muscular
dystrophies. Further studies are needed to compare the cellular
and molecular differences between the adbn
2/2 mouse and other
DGC-related mouse models in order to help dissect the
mechanisms underlying the development of muscular dystrophies.
Materials and Methods
Animals
A breeding pair of adbn
2/2 mice was generously provided by
Dr. R. Mark Grady (Washington University, St. Louis, MO). To
generate adbn
+/2 mice for controls, we outcrossed an adbn
2/2
male (SV129J/ C57Bl/6J mixed background) to an SV129J wild-
type female to obtain adbn
+/2 mice. Subsequent mating between
adbn
+/2 and adbn
2/2 mice provided adbn
2/2 and littermate
control adbn
+/2 animals. Genotypic analyses were performed by
standard PCR methods.
Light and Confocal Microscopy
For light microscopy, muscles were dissected from adbn
2/2 and
adbn
+/2 7 month-old mice, quickly frozen in liquid nitrogen-
cooled isopentane and mounted in O.C.T medium (TissueTek,
Torrance, CA). 10 mm cryosections were cut on a Leica CM3050
cryostat, air-dried and stained with hematoxylin and eosin-
phloxine. Images were obtained on a Zeiss Axiovert 25 microscope
fitted with a Leica DFC300 FX camera using Image Pro Plus 5.1
software.
Costamere images were obtained according to previously
described methods [23]. Mice were trans-cardially perfused with
ice-cold 2% paraformaldehyde in phosphate buffered saline (PBS).
Quadriceps were dissected, adhered to a cryostat chuck with
O.C.T. medium and quickly frozen in liquid-nitrogen slush.
20 mm longitudinal cryosections were cut and stored at -80uC. For
confocal microscopy, sections were thawed, blocked for 30 min-
utes in PBS/BSA (PBS containing 1 mg/ml bovine serum albumin
and 10 mM NaN3) and incubated with a 1:100 dilution of Rabbit
2 polyclonal antibody to dystrophin [25] for 2 hours at room
temperature. Sections were rinsed with PBS/BSA, incubated with
1:200 Alexa-488-conjugated 2u antibody (Molecular Probes,
Carlsbad, CA) for 30 minutes at room temperature and rinsed
with PBS/BSA. To visualize nuclei, 8 mM TO-PRO 3 iodide
(Molecular Probes, Carlsbad, CA) was applied to sections for
5 minutes, rinsed with PBS/BSA and a coverslip applied with a
drop of Slow-Fade Reagent (Molecular Probes, Carlsbad, CA).
Slides were viewed on an Olympus Fluoview 1000 inverted
confocal microscope with a 60x (NA 1.4) oil objective at the
University of Minnesota-Twin Cities Biomedical Imaging Pro-
cessing Laboratory. Laser power and PMT voltage were adjusted
so that 2u antibody alone did not produce signal.
Biochemical Analysis of DGC Stability
Skeletal muscle was dissected, snap-frozen in liquid nitrogen,
and pulverized in a liquid nitrogen-cooled mortar and pestle.
Total muscle homogenates were prepared by solubilizing pulver-
ized muscle in 1% SDS, 5 mM EGTA, and protease inhibitors for
2 minutes at 100uC. The supernatant was collected after brief
centrifugation and its protein concentration determined using the
Bio-Rad DC Protein Assay Kit II (Bio-Rad, Hercules, CA). To
enrich for the DGC, pulverized muscle was solubilized in 10
volumes/g of 50 mM Tris-HCl, 0.5 M NaCl, 1% digitonin and a
cocktail of protease inhibitors for 1 hour at 4uC with gentle
mixing. After high-speed centrifugation, the supernatant was
applied to a WGA-Sepharose column (Sigma-Aldrich, St. Louis,
MO) pre-equilibrated with wash buffer (50 mM Tris-HCl, 0.5 M
NaCl, 0.1% digitonin, and protease inhibitors) for 2 hours at 4uC
to enrich for dystroglycan and associated proteins. The column
was washed and bound proteins eluted with Laemmli sample
buffer (3% SDS and 1% b-mercaptoethanol) at 100uC. Dystro-
phin and b-dystroglycan immunoreactivity in SDS muscle
solubilates (50 mg total protein) and WGA elutes were measured
adbn
2/2 Muscle Function
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antibodies NCL-DYS1 to dystrophin and NCL-b-DG to b-
dystroglycan (Novocastra Laboratories Ltd, Newcastle upon Tyne,
UK). Secondary antibodies were IRDye 800- or IRDye680-
conjugated goat anti-mouse IgG and the fluorescent signals were
detected and quantified using the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE). Relative levels of
dystrophin from WGA elutes were determined by normalizing
dystrophin signals to the corresponding b-dystroglycan signal.
Statistical significance at p,0.05 was determined using a one-
sample t-test.
Ex Vivo Force Measurements
All force measurements were obtained as previously described
[43] from both male and female mice at 2 and 7 months of age.
Experiments were conducted on both the right and left EDL
muscle for each mouse. The EDL muscle was dissected and one
tendon attached to a rigid support and the other to a dual-mode
servomotor. The muscle was allowed to equilibrate in a Ca
2+-
Ringer’s solution continuously gassed with 95% O2/5% CO2 to
maintain a pH of 7.6 at 30uC. Platinum plate electrodes were
positioned on either side of the muscle and stimulation induced by
a single pulse lasting 200 microseconds. The muscle was adjusted
to the optimal length (L0) at which maximal twitch force was
achieved. Muscle was then subjected to an ECC regimen which
consisted of five maximal tetanic stimulations at a frequency of 150
Hertz. Each stimulation was carried out over 700 milliseconds;
over the final 200 milliseconds the muscle was lengthened at a
velocity of 0.5 L0/second resulting in a total stretch of 10% L0.A
five-minute recovery time was allowed between measurements.
The average force produced during a stretch was calculated by
integrating the force-time curve and dividing this value by the
duration of the stretch. Work was calculated by multiplying the
average force produced during a stretch by the length of the
displacement and normalized to muscle mass. Upon completion of
the ECC protocol, muscle was weighed and subsequently bathed
in 0.1% Procion orange, washed, and frozen for cryosectioning.
Cross sectional area of each muscle was calculated according to
Brooks and Faulkner [44] by dividing muscle wet mass by the
product of L0, the EDL fiber-to-muscle length constant 0.44, and
1.06 grams/centimeter
3, the density of mammalian skeletal muscle
[44]. Differences between genotypes at each time point were
assessed by using a Student’s two-tailed t-test for independent
samples to determine significance at p,0.05.
In Vivo Physiological Performance
The WBT protocol was carried out as previously described [43].
A mouse was attached by the tail to a horizontally mounted force
transducer using suture silk and subsequently placed in an
apparatus that allowed only forward movement. The force evoked
by gentle tail pinches (approximately 5 pinches per minute) was
recorded for 5 minutes and the top 5 values were identified and
normalized to body mass.
Maximal exercise performance was tested on a Columbus
Instruments treadmill with an uphill grade of 15u. Mice were
acclimated to the treadmill by running at a speed of 10 meters per
minute for 5 minutes, three times a week, for two weeks. To
determine maximal exercise performance mice were run on the
treadmill for 5 minutes, at a speed of 10 meters per minute,
followed by a 1 meter per minute increase in speed every minute
until exhaustion. Mice were considered exhausted when they
refused to stay off a shock bar for at least 5 seconds. Maximal
exercise capacity was determined as the average duration of two
trials separated by two days. Differences between adbn
+/2 and
adbn
2/2 mice at each time point were assessed by using a
Student’s two-tailed t-test for independent samples to determine
significance at p,0.05.
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